A grapefruit a day for patients infected with hepatitis C?
Peter N. Morcos, Barbara Brennan, Patrick F. Smith – 28 May 2008
MicroRNA expression profiling: A molecular tool for defining the phenotype of hepatocellular tumors
Chiara Braconi, Tushar Patel – 28 May 2008
Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C
Simone Carotti, Sergio Morini, Stefano Ginanni Corradini, Maria Antonella Burza, Antonio Molinaro, Guido Carpino, Manuela Merli, Adriano De Santis, Andrea Onetti Muda, Massimo Rossi, Adolfo Francesco Attili, Eugenio Gaudio – 28 May 2008 – Activated alpha‐smooth muscle actin (α‐SMA)–positive hepatic stellate cells (HSCs) are pericytes responsible for fibrosis in chronic liver injury. The glial fibrillary acidic protein (GFAP), commonly expressed by astrocytes in the central nervous system, is expressed in vivo in the liver in a subpopulation of quiescent stellate cells.
Hepatocellular carcinoma development requires hepatic stem cells with altered transforming growth factor and interleukin‐6 signaling
Nicholas A. Shackel, Geoffrey W. McCaughan, Fiona J. Warner – 28 May 2008
Molecular adsorbents recirculating system (MARS) and the failing liver: A negative editorial for a positive trial?
Vicente Arroyo, Javier Fernandez, Antoni Mas, Angels Escorsell – 28 May 2008
Erratum
28 May 2008
Low recurrence of preexisting extrahepatic malignancies after liver transplantation
Daniel Benten, Martina Sterneck, Jens Panse, Xavier Rogiers, Ansgar W. Lohse – 28 May 2008 – The incidence of de novo malignancies is increased in organ transplant recipients, and patients with hepatic carcinomas are at high risk for tumor recurrence after liver transplantation. Data about recurrent cancer after orthotopic liver transplantation (OLT) in patients with a history of nonhepatic malignancy are very limited. We retrospectively analyzed data from 606 adult OLT recipients and identified 37 patients (6.1%) with a preexisting extrahepatic malignancy.
ImmuKnow: A new parameter in immune monitoring of pediatric liver transplantation recipients
Moshe Israeli, Tirza Klein, Benjamin Sredni, Yaron Avitzur, Eitan Mor, Nathan Bar‐Nathen, Ran Steinberg, Gabriel Dinari, Rivka Shapiro – 28 May 2008 – Lifelong immunosuppression is mandatory for optimal graft and patient survival following liver transplantation. Nevertheless, graft rejection or numerous adverse events associated with overimmunosuppression or underimmunosuppression cannot be completely avoided. The ImmuKnow assay measures cell‐mediated immunity and is able to discern between conditions of overimmunosuppression and underimmunosuppression.
Prevention of hepatitis B recurrence after living donor liver transplantation: Primary high‐dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy
Shin Hwang, Sung‐Gyu Lee, Chul‐Soo Ahn, Ki‐Hun Kim, Deok‐Bog Moon, Tae‐Yong Ha, Gi‐Won Song, Dong‐Hwan Jung, Jung‐Ik Park, Je‐Ho Ryu, Hyo‐Jun Lee, Dong‐Jin Suh, Young‐Suk Lim – 28 May 2008 – The prevention of hepatitis B virus (HBV) recurrence is essential after liver transplantation in patients infected with HBV. We evaluated the efficacy of primary high‐dose hepatitis B immunoglobulin (HBIG) monotherapy and rescue antiviral therapy in 639 HBV‐infected adult patients who underwent living donor liver transplantation (LDLT) between February 1997 and December 2004.
Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice
Kun L. Ma, Xiong Z. Ruan, Stephen H. Powis, Yaxi Chen, John F. Moorhead, Zac Varghese – 27 May 2008 – The prevailing theory in non‐alcoholic fatty liver disease (NAFLD) is the “two‐hit” hypothesis. The first hit mainly consists of lipid accumulation, and the second is subsequent systemic inflammation. The current study was undertaken to investigate whether inflammatory stress exacerbates lipid accumulation in liver and its underlying mechanisms.